2. Search Result
Search Result
Results for "

AKR1C4

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Recombinant Proteins

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2901
    3α-Hydroxysteroid Dehydrogenase, Microorganism

    3α-HSD

    		 Endogenous Metabolite Endocrinology
    3α-Hydroxysteroid Dehydrogenase, Microorganism (3α-HSD) is an enzyme encoded by the AKR1C4 gene, which can catalyze the conversion of 3-ketosteroids into 3α-hydroxy compounds. 3α-Hydroxysteroid dehydrogenase plays an important role in the inactivation of androgen DHT, and can convert DHT into 3α-androstanediol with weak androgen activity, which can be used in the research of hirsutism .
    3α-Hydroxysteroid Dehydrogenase, Microorganism
  • HY-150644
    S07-2010
    1 Publications Verification

    		 Aldose Reductase Cancer
    S07-2010 is a potent pan-AKR1C (aldo-keto reductase family 1 member C) inhibitor, with IC50 values of 0.19, 0.36, 0.47, and 0.73 μM for AKR1C3, AKR1C4, AKR1C1 and AKR1C2, respectively. S07-2010 induces apoptosis in A549/DDP cells. S07-2010 strengthens the cytotoxicity of chemotherapeutic agents in drug-resistant cells. S07-2010 significantly inhibits the proliferation of drug-resistant cells .
    S07-2010
  • HY-RS00537
    AKR1C4 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    AKR1C4 Human Pre-designed siRNA Set A contains three designed siRNAs for AKR1C4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    AKR1C4 Human Pre-designed siRNA Set A
    AKR1C4 Human Pre-designed siRNA Set A
  • HY-150649
    S07-2005 (racemic)

    		17β-HSD Cancer
    S07-2005 racemic is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 0.13 μM and 0.75 μM for AKR1C3 and AKR1C4, respectively. S07-2005 racemic has potential as a chemotherapeutic potentiator for cancer agent resistance .
    S07-2005 (racemic)
  • HY-173132
    AKR1Cs-IN-1

    		Aldose Reductase Cancer
    AKR1Cs-IN-1 (Compound 29) is a potent and broad-spectrum inhibitor targeting members of the Aldo-Keto Reductase 1C family (AKR1C1-1C4). By simultaneously occupying the SP2 and SP3 pockets, it effectively inhibits multiple isoforms and disrupts metabolic pathways associated with drug resistance. In enzymatic activity assays, AKR1Cs-IN-1 exhibited significant inhibitory potency, with IC50 values of 0.09, 0.28, 0.05, and 0.51 µM against AKR1C1, AKR1C2, AKR1C3, and AKR1C4, respectively. In the doxorubicin (DOX)-resistant breast cancer cell line MCF-7/ADR, AKR1Cs-IN-1 showed remarkable resensitization effects and significantly enhanced the cytotoxicity of DOX. AKR1Cs-IN-1 holds promise for research on overcoming drug resistance in breast cancer .
    AKR1Cs-IN-1
  • HY-124432
    CRT0093964

    		Aldose Reductase Cancer
    CRT0093964 is an isoform-selective non-carboxylate inhibitor of AKR1C3 (IC50=0.11 μM) with no activity against AKR1C1, AKR1C2, AKR1C4, COX-1, and COX-2.CRT0093964 can be used for the research of leukemia, hormone-related cancers, colon cancer .
    CRT0093964
  • HY-W069545
    (S)-1-Tetralol

    		Biochemical Assay Reagents Others
    (S)-1-Tetralol is a substrate of AKR1C1, AKR1C2, AKR1C3, and AKR1C4, with Kms of 8, 22.5, 165, and 25 μM, respectively .
    (S)-1-Tetralol
  • HY-181542
    SG-55

    		Aldose Reductase Cancer
    SG-55 is a selective, noncompetitive and orally active AKR1C3 inhibitor with an IC50 of 5 nM and a Ki of 10 nM. SG-55 shows >2000-fold selectivity for AKR1C3 over AKR1C1, AKR1C2, and AKR1C4 (> 10 μM). SG-55 increases the ratio of reduced/oxidized nicotinamide adenine dinucleotide phosphate (NADPH/NADP +), decreases the ratio of reduced/oxidized glutathione (GSH/GSSG), and induces DNA double-strand breaks. SG-55 can overcome Osimertinib (HY-15772) resistance mediated by EGFR C797S triple mutation in non-small cell lung cancer (NSCLC) .
    SG-55
  • HY-123732
    CRT0083914

    		17β-HSD Cancer
    CRT0083914 is a subtype-selective non-carboxylate inhibitor of AKR1C3. CRT0083914 is applicable to the research of colon cancer .
    CRT0083914

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: